Latuda set for stronger growth on US bipolar depression OK
This article was originally published in Scrip
Dainippon Sumitomo Pharma's (DSP) Latuda (lurasidone) has become the first atypical antipsychotic to be approved in the US specifically for the treatment of major depressive episodes associated with bipolar I depression in adults either as monotherapy or adjunctive treatment to background therapy with lithium or valproate.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.